sary for the organization of embryonic vasculature (Fong Genentech, Inc. et al., 1995; Shalaby et al., 1995) . Department of Protein Engineering KDR and Flt-1, together with the related receptor Flt-4, South San Francisco, California 94080 constitute a subgroup of the platelet-derived growth factor (PDGF) receptor family (Van der Greer and Hunter, 1994) . Flt-1 binds VEGF in the pM range and has a 10-fold higher affinity for VEGF than KDR, while Flt-4 Summary does not bind VEGF (Davis-Smyth et al., 1996) . In addition to the VEGF receptor subgroup and the PDGF ␣ Vascular endothelial growth factor (VEGF) is a homodiand ␤ receptors, the PDGF receptor family includes Fms meric hormone that induces proliferation of endothe-(the macrophage colony-stimulating factor receptor) lial cells through binding to the kinase domain receptor and Kit (the stem cell factor receptor). The extracellular and the Fms-like tyrosine kinase receptor (Flt-1), the portion of these receptors is comprised of a number of extracellular portions of which consist of seven immuimmunoglobulin domains, 7 for the VEGF subgroup and noglobulin domains. We show that the second and 5 for the other members. Domain deletion studies on third domains of Flt-1 are necessary and sufficient resides within the first three domains. Deletion experidomain 2 in a predominantly hydrophobic interaction ments on KDR show that only domains 2 and 3 are with the "poles" of the VEGF dimer. Based on this critical for ligand binding, and that domains 4-7 are not structure and on mutational data, we present a model essential for signaling (Fuh et al., submitted). In addition, of VEGF bound to the first four domains of Flt-
a Binding affinities were measured as described in the Experimental Procedures. The relative affinity was derived from averaging three independent measurements with standard errors of Ϯ15%-25%. b The EC 50 is the half-maximally effective concentration of MAb for binding to the receptor deletion construct. c ND, not detectable. These data define the binding epitope for MAFL3 to be domain one.
near wild-type affinity, and that domain 2 by itself binds Given the ability of the constructs of domains 1-2 and 2-3 to bind VEGF tightly, the affinity of domain 2 alone VEGF only about 60-fold weaker than the entire extracellular portion. The crystal structure of the complex is the (residues 129-229) for VEGF was tested. Nonglycosylated domain 2 (Flt-1 D2 ) was produced from E. coli and first example of a cystine-knot growth factor bound to a domain of its receptor. VEGF uses its receptor-binding found to bind with an affinity of 1 nM, or about 60-fold more weakly than the monomeric version of the entire face to bind Flt-1D2 in a predominantly hydrophobic interaction. Flt-1D2 has several unique features compared to ectodomain of Flt-1 (Table 1) . This difference in affinity is approximately the same as that between the IgG fuother domains of the immunoglobulin superfamily (IgSF), including the other domains of its own extracellular porsions of domains 1-2 and 1-7, showing that glycosylation is not important for binding. Competition for native tion; these features are probably conserved in the second domain of other members of the PDGF receptor ligand between Flt-1 D2 and intact receptors was demonstrated by the ability of Flt-1 D2 to inhibit VEGF 165 -stimufamily. We propose a model of VEGF in complex with domains 1-4 of its receptor that may be a general examlated proliferation of human umbilical vein endothelial cells with an IC 50 of about 180 nM ( Figure 1 ). This IC 50 ple of how receptors of the PDGF family bind their ligands.
is 300-fold higher than the IC 50 for the dimeric IgG fusion of the entire extracellular portion, in good agreement with the 110-fold lower binding constant (Table 1) . Results
Determination of Minimal VEGF-Binding Fragments
Structure Determination Systematic carboxy-terminal deletions of the seven IgSF Crystallization of the complex between VEGF 8-109 and domains of Flt-1 were carried out to define the minimal Flt-1D2 yielded two crystal forms, diffracting to 1.7 Å domain(s) sufficient for high-affinity binding to VEGF. and 2.7 Å , respectively (Table 2) . These crystal forms The deletion variants were first expressed in mammalian contained 1 and 2 dimeric complexes per asymmetric cells as proteins fused to the Fc portion of IgG (Fuh et al., submitted) . The domain borders were chosen based on homology to other IgSF members (Williams and Barclay, 1988; Finnerty et al., 1993) . The proper folding of all variants was verified by their ability to bind several anti-Flt-1 monoclonal antibodies (partly shown in Table  1 ), three of which entirely (MAFL6) or partially (MAFL1 and -8) block ligand binding. The deletions caused very little change in binding to VEGF8-109, until domain 3 was removed from the 1-3 construct, which resulted in a 20-fold reduction in affinity (Table 1) . Deletion of domain 1 did not affect binding significantly (Table 1) . To test the magnitude of possible avidity effects, monomeric glycosylated versions were produced from IgG fusions of domains 1-7 and 1-3 that contained an engineered is only slight. unit, respectively, allowing us to make extensive use which is comparable to the rms deviation of 0.45-0.80 Å calculated for the four copies of free VEGF8-109. The of noncrystallographic symmetry averaging. The highresolution crystal structure was refined to an R value of largest differences are observed for loop regions 42-48 and 85-89, which have also been shown to vary in free 19.9% (Rfree ϭ 26.1%), using all reflections with F greater than 0.2 between 20 and 1.7 Å resolution (Table 2) .
VEGF8-109 (Muller et al., 1997b) . All nonglycine residues have their main-chain torsion angles in the "most favorable" or in the "additionally allowed" regions (Laskowski et al., 1993) (␤aЈ, ␤c, ␤cЈ, ␤f, and ␤g) , the other of 3 (␤b, ␤d, and ␤e) (Figure 2 ). The strands in the three-stranded sheet are by two disulfide bridges between Cys-51 and Cys-60. It has a rather unusual shape, with a maximum elongarather short and consist of only 3 or 4 residues. In contrast, the five-stranded sheet is more substantial, and tion of about 70 Å and a flat central part that barely spans 15 Å . A segment (residues 16-24) near the N terminus of strands ␤f and ␤g are 9 and 11 residues long, respectively. The crossover connection between strands ␤e each subunit forms helix ␣1, which folds on top of the other monomer in the biologically active dimer. A highly and ␤f includes a single helical turn at residues 199-201. A disulfide bond between Cys-158 and Cys-207, conirregular four-stranded ␤ sheet comprising strands ␤1, ␤3, ␤5, and ␤6 (Muller et al., 1997a) forms the central necting the segment immediately following strand ␤b to strand ␤f, is buried in the hydrophobic core. part of the molecule. Two short strands, ␤4 and ␤7, are extensions of ␤3 and ␤6, classified separately because
The most unusual feature of Flt-1 D2 is the conformation of the N-terminal segment preceding strand ␤aЈ. Instead of an interruption of the hydrogen bonding pattern. The connection between ␤1 and ␤3 contains a short ␣-helical of pairing up with neighboring strand ␤g and forming what is strand ␤a in more standard IgSF domains, resisegment followed by a loop and strand ␤2, which is hydrogen-bonded to strand ␤5. This short, three-stranded dues 137-143 bulge away from the main body of the protein (Figure 2 ). This bulge is anchored at its C-termisheet at the end of the molecule opposite to the cystine knot in combination with helix ␣1 from the other subunit nal end by strand ␤aЈ and at its beginning by the side chain of Phe-135, which is buried in the hydrophobic was identified as VEGF's receptor-binding face (Muller et al., 1997a) . core ( Figure 3A ). Because several of the residues in this bulge are in contact with VEGF (below), this bulge might The overall structure of VEGF in complex with Flt-1 D2 is identical to the previously reported structure be a consequence of complex formation; thus, the possibility exists that free Flt-1 D2 adopts a more canonical of free VEGF 8-109 (Muller et al., 1997a (Muller et al., , 1997b , and no major conformational changes are observed on Flt-1 D2 IgSF conformation. Four distinct classes of IgSF domains have been charbinding. The two monomers in the complex have a rootmean-square (rms) deviation of 0.64 Å for 94 C␣ atoms, acterized, the V, C1, C2, and I sets (Harpaz and Chothia, conserved among I-set members is leucine in Flt-1D2; the smaller size of the Leu-169 side chain is compensated for by other buried residues nearby.
The VEGF-Flt-1D2 Interface
The overall structure of the complex follows the internal approximate two-fold symmetry of the VEGF dimer (Figure 4) . However, the differences in crystal packing environment between the two individual molecules do introduce some differences in orientation. Superposition of the entire complex onto itself, rotated around the local two-fold symmetry axis, results in a rather large rms deviation of 1.54 Å for 376 C␣ atoms. This difference is accounted for by small rotations of the individual Flt-1D2 molecules with respect to the VEGF dimer, pivoted around the interface. The two interfaces themselves are The termini and the secondary structure elements as defined by the these two residues from the calculation, the total surface VEGF in contact with Flt-1 D2 include residues from the N-terminal helix (16-27), the loop connecting ␤3 to ␤4 (61-66) and strand ␤7 (103-106) of one monomer, as 1994). The structure shows that Flt-1 D2 is a distant memwell as residues from strand ␤2 (46-48) and from strands ber of the I set, despite significant differences from ca-␤5 and ␤6 together with the connecting turn (79-91) of nonical I-set structures. Flt-1 D2 has a strand topology the other. Flt-1 D2 faces VEGF with the "bottom" half of that is similar to that of I-set member telokin (Holden its five-stranded sheet (Figure 2 ), a surface made up et al., 1992) and can be superimposed on the telokin of residues from the N-terminal bulge, strand ␤aЈ, part structure with an rms difference of 1.4 Å (66 C␣ atoms of strands ␤g and ␤f, the loop connecting strands ␤c within a distance cutoff of 3.0 Å ). Of the 20 key positions and ␤cЈ, and the helical turn connecting strands ␤e in the V-frame profile that define the I set (Harpaz and and ␤f. Chothia, 1994) , only 14 fulfill the required criteria in Flt- Figure 5 shows a space-filling rendering of the sur-1 D2. The other 6 positions all involve residues displayed faces buried in the interface between VEGF 8-109 and from the five-stranded sheet. Two differences are found Flt-1 D2 . The interface is dominated by hydrophobic conin the so-called "Y-corner" motif, a sequence consisting tacts, which make up almost 70% of the total buried of residues D-
surface. Altogether, of 21 ligand and 26 receptor resi-1994), at the N-terminal end of strand ␤f. The first aspardues contributing to the interface, 9 are leucine or isoleutic acid is replaced conservatively by Glu-201, and the cine residues, accounting for 24% of the total buried tyrosine residue by Leu-205. Usually, the tyrosine hysurface. It is noteworthy that both the surface of the droxyl group forms a hydrogen bond to the carbonyl ligand and the surface of the receptor are rather flat and oxygen of the first residue of the motif. In Flt-1 D2 , this lack a predominant knob-into-hole interaction. The only hydrogen-bonding function is fulfilled instead by Thr-222 direct polar interaction is a bidentate set of chargefrom strand ␤g, which is normally a key hydrophobic mediated hydrogen bonds between the side chains of residue ( Figure 3B ). The overall conformation of this Arg-224 of Flt-1 D2 and Asp-63 of VEGF ( Figure 3C ). In region remains very similar to the standard Y-corner addition, 14 buried solvent molecules are found in the motif; thus, this alternative set of residues constitute a interface, 7 of which bridge between the ligand and the variation of this structural feature. Strand ␤g contains receptor (see Figure 3C ). Three water molecules are two other sites, which in Flt-1D2 are occupied by trapped in a cavity near the center of the interface, and Arg-224 instead of strictly hydrophobic residues.
formed by Asn-62, Tyr-21, and Lys-48 of VEGF and IleThe side chain of Tyr-220 occupies the position taken 202, Gly-203, Thr-222, and His-223 of Flt-1D2. by strand ␤a in telokin; therefore, this change may be related to the unusual bulging N-terminal segment of Discussion Flt-1 D2 . Interestingly, Arg-224 has a special function as ligand binding determinant, because its side chain Domain 2 of Flt-1 Is Sufficient for Tight makes intimate charge-mediated hydrogen bonding in-VEGF Binding teractions with VEGF ( Figure 3C ; see below). Finally, a Dimerized forms of KDR bind about 100-fold more tightly than their corresponding monomeric forms (Fuh et al., buried tryptophan residue on strand ␤c that is strictly submitted), while dimerized forms of Flt-1 bind only sensitivity limit of the assay. At any rate, monomeric Flt-1 binds VEGF about 100-fold more tightly than mono-2-fold more tightly. The reason for the difference in avidity could be that receptor-receptor interactions in dimermeric KDR. Our deletion analysis of Flt-1 shows that domains 2-3 ized receptors would not add significantly to the binding energy of monomeric Flt-1 constructs binding tightly to are sufficient for binding VEGF 8-109 with near wild-type affinity. Similar results were found for deletions in KDR both poles of VEGF. Alternatively, the high affinity of monomeric Flt-1 for VEGF could have reached the (Fuh et al., submitted) . Further deletion of domain 3 of
The discrepancy is likely due to the choice of domain boundaries. This can now be rationalized, because the structure shows that the previous deletions either cut into the last ␤ strand of the second domain or had extra residues that presumably destabilize the overall folding. The importance of domain 2 for biological function is demonstrated by the observation that it contains epitopes for the three neutralizing antibodies and that it can inhibit the activity of VEGF 165 in a human endothelial cell proliferation assay.
Comparison with the KDR Binding Site Deduced from Mutagenesis Data
A comprehensive mutagenesis study of VEGF has enabled us to identify its receptor-binding determinants for KDR and to define its receptor-binding face (Muller et al., 1997a) . Of the 7 VEGF residues that were found to be of moderate to great importance for tight binding to KDR, 5 are buried in the interface with Flt-1D2 in the structure of the complex ( Figure 5 ), suggesting that the binding sites for KDR and Flt-1 are very similar. The remaining two binding determinants for KDR are Glu-64 and Ile-43, for which alanine substitution resulted in 110-and 20-fold decreased affinity, respectively. These residues are located just outside the contact region with
The two monomers of VEGF are shown in red and blue, respectively; the two copies of Flt-1 D2 in green. The secondary structure
Flt-1 D2 (see Figure 5 ) and form part of a groove that elements of VEGF 8-109 as well as all terminal residues are labeled.
connects the "pole" to the "bottom" face of VEGF. The gests that in the native complex, these residues may contact the third domain of the receptor. Flt-1, however, only causes a 20-fold decrease in affinity, compared to a larger than 1000-fold decrease for KDR.
Location of Domains 1 and 3 in the Native Complex
The second domain of Flt-1 uses the C-terminal half of Thus, the relative importance of domain 3 is different for Flt-1 and KDR. Flt-1 D2 produced from E. coli binds its five-stranded sheet to bind to the pole of the flat and elongated VEGF dimer. This orientation places the N VEGF8-109 with an affinity similar to that of a glycosylated construct of domains 1-2. This is consistent with previterminus of Flt-1D2 at a distance of 28 Å from VEGF8-109, pointing away from the ligand (see Figure 4) . Moreover, ous studies showing that glycosylation of Flt-1 is not important for binding (Barleon et al., 1997) . However, our domain deletion studies show that deletion of domain 1 only affects binding affinity by two-fold or less. these results contradict reports suggesting that domain 2 by itself is not sufficient for binding (Davis-Smyth, Therefore, we believe it is unlikely that the first domain of Flt-1 interacts directly with the ligand in the native 1996; Barleon et al., 1997; Cunningham et al., 1997) . (Muller et al., 1997a) . Binding determinants are colorcoded based on the magnitude of the decrease in binding upon alanine substitution (dark red, Ͼ100-fold; orange, 50-to 100-fold; yellow, 10-to 50-fold; light yellow, 3-to 10-fold). (Center and Right) Buried surface between VEGF 8-109 (center) and Flt-1D2 (right). Contact residues are color-coded in different shades of red, reflecting the percentage of accessible surface buried in the interface (dark red, 75%-100%; orange, 50%-75%; yellow, 25%-50%; light yellow, 0%-25%). The two VEGF images have been adjusted to create a wall-eyed stereo view of the surface; note the groove between residues 64 and 43. Model generated using the program CONIC (Huang et al., 1991) . Human sequences were taken from 1 D2 in tube representation, generated using the program GRASP the SwissProt Data Bank (accession numbers P17948, P35968, (Nicholls et al., 1993) and color-coded for electrostatic potential.
P35916, P09619, P16234, P07333, and P10721). Blue and red indicate positively and negatively charged patches on the surface of VEGF 8-109 , respectively; selected VEGF residues are labeled. The C terminus of Flt-1 D2 reaches toward a groove between Glu-64 and Ile-43. Glu-64 is an important binding determinant of Using the structures of Flt-1D2 and telokin (Holden et VEGF for binding to Flt-1 (Keyt et al., 1996b) , and both of these al., 1992) as templates, we built models of the individual residues are important for high-affinity binding of VEGF to KDR domains 1, 3, and 4 of Flt-1. We then constructed a (Muller et al., 1997a) . domain 1 points away from the ligand, the domain 2-3 linker occupies the groove in VEGF, and domain 3 is in contact with its "bottom" face. The likely orientation of complex. If this is true, a possible function for this dothe two copies of domain 3 places their C-terminal ends main might be that in the absence of ligand it shields in close proximity, suggesting direct receptor-receptor the hydrophobic surface of domain 2, and then is discontacts between domains 4 ( Figure 6B ). This function placed by VEGF upon complex formation.
of domain 4 agrees with previous proposals that it may Compared to domain 2 alone, a construct of domains be involved in receptor dimerization of Flt-1 (Barleon et 2 and 3 binds VEGF about 20-fold tighter. This observaal., 1997). tion, combined with the analysis of the mutagenesis data in light of our crystal structure, strongly suggests that domain 3 is involved in direct contacts with the Implications for Other PDGF Receptor Family Members ligand. In the structure of the complex, the C-terminal three residues of Flt-1 D2 are disordered, but the visible Sequence alignment of the members of the PDGF receptor family reveals that their first four domains have many C-terminal end extends toward a 6.5 Å wide groove between the monomers, which connects the pole of of the key I-set residues, suggesting that they all belong to the I set of the IgSF. Furthermore, many of the unique VEGF to its membrane-facing side ( Figure 6A ). The walls of this groove are formed by the side chains of Asp-63 features of Flt-1 D2 are conserved in the second domain of the other members, suggesting that they share similar and Glu-64 on one side, and Ile-43, Ile-46, and Tyr-36 on the other, while the bottom is made of Asp-34 and structural characteristics distinct from the other domains of these receptors (Figure 7 ). For example, the Ser-30. The groove appears barely wide enough to accommodate a polypeptide chain, but the residues formcharacteristic core tryptophan residue of strand ␤c is always a leucine in the second domain. Residue Pheing the walls reside on flexible regions of VEGF 8-109 in its free state (Muller et al., 1997b) . Furthermore, the side 135 of Flt-1D2, anchoring the N-terminal bulge to the core of the domain, is conserved as phenylalanine (tryptochains of Phe-36 and Ile-46 adopt different conformations in the two copies of VEGF8-109 in our complex, phan in Fms) in domain 2 of all receptors of the PDGF family, suggesting that the distinctive bulge of Flt-1D2 suggesting an additional mechanism for widening the groove. Based on these observations, we suggest that may be present in some of the other members as well. In Flt-1D2, strand ␤b comprises only three residues and in the native complex the linker between domains 2 and 3 may occupy the groove, positioning the third domain is terminated by a Pro-Cys motif, which is conserved in all second domains except that of Kit. The ␤e strand in contact with the "bottom" face of VEGF. (We believe the reason for the disordered C terminus of our construct contains a strictly conserved Gly-191, leaving room to accommodate the side chain of Trp-186, which is conmay be that electrostatic repulsion between the artificial C terminus and Glu-64 and Asp-34 of VEGF prevents served as an aromatic residue in all members except Kit. Finally, the linker region between domains 1 and 2 the chain from entering the groove.) , then dipped in mains 1-7, shows that residues 1-26 constitute the signal sequence.
artificial mother liquor brought to 10% glycerol and flash-frozen in For expression of domain 2 alone, residues 129-229 of Flt-1 were liquid nitrogen. A 1.7 Å data set from a form A crystal was collected constructed in a phagemid vector under the control of an alkaline on an ADSC 1K CCD detector at the Cornell High Energy Synchrophosphatase promoter and stII secretion signal.
tron Source on beam line A1, ϭ 0.908 Å . For form B, data to 2.7 Å resolution were collected on a MAR-Research imaging plate system using a Rigaku rotating anode generator with mirror-focused Binding Assays Receptor binding assays using [
125 I]VEGF165 (ICN, DuPont) and CuK␣ radiation. The data sets were reduced using programs DENZO and SCALEPACK (Otwinowski, 1993) (Table 2) . monoclonal antibody binding assays were done as described elsewhere (Fuh et al., submitted) . Briefly, receptor-IgG fusions or monomers were incubated with [ 125 I]VEGF165 and increasing concentraStructure Determination and Refinement tions of VEGF for 18 hr at room temperature in 100 l of binding The structure was determined by molecular replacement and buffer containing 0.5% bovine serum albumin, 0.05% Tween 20, 0.15 6-fold noncrystallographic symmetry averaging across the two crys-M NaCl, and 20 mM Tris-HCl (pH 7.5). The mixture was transferred to tal forms. Using the program AMoRe (CCP4, 1994) and the high a 96-well plate coated with anti-Fc antibody for Flt-1-IgG assays or resolution structure of the free VEGF 8-109 dimer (Muller et al., 1997b ) MAFL3 for Flt-1 monomer assays and allowed to equilibrate for 15 as a search model, clear solutions were found for one dimer in the min before washing and counting the plate. For binding assays form A cell and two independent dimers in the form B cell. The initial with E. coli-expressed domain 2, biotinylated VEGF 8-109 was used.
R values for all data between 12 and 4 Å were 48.2% and 49.2% Dilutions of purified Flt-1 D2 were incubated with 0.5 nM of biotinyfor the A and B crystal forms, respectively. Attempts to place models lated VEGF 8-109 for 2 hr on a 96-well plate coated with an anti-VEGF of Flt-1 D2 failed. monoclonal antibody that competes with Flt-1 D2 binding before addTo identify the position of the Flt-1 D2 molecules, a mask with a ing horseradish peroxidase-conjugated Streptavidin (Jackson Imradius of 30 Å was created around the VEGF 8-109 molecules in the A munoResearch Lab, Inc., West Grove, PA).
cell and then transferred to the B cell. After overlap removal with program NCSMASK (CCP4, 1994) in both crystal forms, the edited [ 3 H]Thymidine Incorporation Assay mask was used for solvent flattening and 6-fold cross-crystal averFor assays with human umbilical vein endothelial cells (purchased aging with program DMMULTI (CCP4, 1994), using the symmetry from Cell System, Kirkland, WA), cells were seeded in 96-well plates operators relating the VEGF 8-109 molecules to each other. The re-(2000 cells per well) and fasted in DMEM F12 media with 1% DFBS sulting electron density was partially interpretable for 5 of the 6 for 24 hr. VEGF165 (0.2 nM) together with increasing concentrations expected Flt-1 D2 molecules and allowed building of about 60% of of the Flt-1 variants was added in fresh fasting media, incubated the known sequence. Symmetry operators relating the resulting for 18 hr, and pulsed with [ 3 H]thymidine (0.5 Ci/well) for 24 hr, after fragments were optimized by rigid body refinement using the prowhich the cells were harvested and counted.
gram X-PLOR (Brü nger et al., 1987) , and the refined positions were used to improve the mask. The refined symmetry operators, improved mask, and phase inforRefolding and Purification VEGF8-109 was expressed, refolded, and purified as described mation from the VEGF8-109 molecules and the partial model of Flt-1D2 were used in a subsequent averaging procedure, resulting in greatly (Christinger et al., 1996) . A construct comprising residues 129-229 of Flt-1, corresponding to the second IgSF domain, was expressed improved electron density maps. Subsequent model building and refinement were done in crystal form A, using the programs O (Jones Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. et al., 1991) , X-PLOR (Brü nger et al., 1987), and REFMAC (CCP4, 1994) . A random set of 2275 reflections was sequestered and used 146, 1029-1039. to monitor the free R value (Brü nger, 1992) . Alternate cycles of Ferrara, N. (1995) . The role of vascular endothelial growth factor in refinement and model building, accompanied by addition of water pathological angiogenesis. Breast Cancer Res. Treat. 36, 127-137. molecules, and inclusion of a solvent mask (k ϭ 0.39 e/Å 3 , B ϭ Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, 65 Å 2 ), resulted in the final model with Rfree ϭ 26.1% and good K.S., Powell-Braxton, L., Hillan, K.J., and Moore, M.W. (1996) . Hetstereochemistry (see Table 2 ). Structural comparisons were done erozygous embryonic lethality induced by targeted inactivation of using the program O, with a distance cutoff of 3.8 Å unless otherwise the VEGF gene. Nature 380, 439-442. indicated.
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Model Building
Molecular cloning of murine FLT and FLT4. Oncogene 8, 2293-2298. The 20 I-set domain fingerprint residues were identified in the seFong, G.-H., Rossant, J., Gertsenstein, M., and Beritman, M.L. quences of domains 1, 3, and 4 of Flt-1, and models of these domains (1995) . Role of the flt-1 receptor tyrosine kinase in regulating the were built using the structures of Flt-1 D2 and telokin as templates.
assembly of vascular endothelium. Nature 376, 66-70. Domains 1 and 2 were connected through an eight-residue linker.
Harpaz, Y., and Chothia, C. (1994) . Many of the immunoglobulin Domain 3 was built with a bulge in its N-terminal segment like that superfamily domains in cell adhesion molecules and surface recepobserved in domain 2; this bulge was placed in the groove of VEGF tors belong to a new structural set which is close to that containing connecting its pole to its "bottom" face. This arrangement posivariable domains. J. Mol. Biol. 238, 528-539. tioned the C-terminal ends of the two symmetry-related copies of Hemmingsen, J.M., Genert, K.M., Richardson, J.S., and Richardson, domain 3 close to each other. Domain 4 was placed in intimate D.C. (1994) . The tyrosine corner: a feature of most greek key ␤-barrel contact with its symmetry mate, using an eight-residue link from proteins. Prot. Sci. 3, 1927 Sci. 3, -1937 . domain 3.
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